Antibody-DM1 conjugates as cancer therapeutics

Cancer Letters

Volumn 307, Issue 2, 2011, Pages 113-118

  Lopus, Manu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; DM1; Maytansinoid; Microtubule; Tubulin

Indexed keywords

ANTINEOPLASTIC AGENT; BIIB 015; CANTUZUMAB MERTANSINE; CANTUZUMAB N2' DEACETYL N2' (3 MERCAPTO 1 OXOPROPYL)MAYSANSINE CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMGN 388; LORVOTUZUMAB MERTANSINE; MAYTANSINE; MLN 2704; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C242 N2' DEACETYL N2' (3 MERCAPTO 1 OXOPROPYL)MAYSANSINE CONJUGATE; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY N2' DEACETYL N2' (3 MERCAPTO 1 OXOPROPYL)MAYSANSINE CONJUGATE; N2' DEACETYL N2' (3 MERCAPTO 1 OXOPROPYL)MAYSANSINE; N2' DEACETYL N2' (4 MERCAPTO 4 METHYL 1 OXOPENTYL)MAYSANSINE; TRASTUZUMAB MAYSANSINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL DEATH; COLORECTAL CANCER; CONJUGATE; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STRUCTURE; HUMAN; LUNG CARCINOMA; MICROTUBULE; MITOSIS INHIBITION; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY;

EID: 79957667944     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.017     Document Type: Review

References (50)

1. M. Lopus, M. Yenjerla, L. Wilson, Microtubule Dynamics, in: T.P. Begley (Ed.), Wiley Encyclopedia of Chemical Biology, vol. 3, Wiley, NJ, 2009, pp. 153-160.
2. A.T. Fojo, In the Role of Microtubules in Cell Biology, Neurobiology, and Oncology (Cancer Drug Discovery and Development), Humana Press, New York, 2009.
3. Dave R.H., Saengsawang W., Lopus M., Dave S., Wilson L., Rasenick M.M. A molecular and structural mechanism for G-protein mediated microtubule destabilization. J. Biol. Chem. 2011, 286:4319-4328.
4. Dumontet C., Jordan M.A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 2010, 9:790-803.
5. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4:253-265.
6. Kupchan S.M., Komoda Y., Court W.A., Thomas G.J., Smith R.M., Karim A., Gilmore C.J., Haltiwanger R.C., Bryan R.F. Maytansine a novel antileukemic ansa macrolide from Maytenus ovatus. J. Am. Chem. Soc. 1972, 94:1354-1356.
7. Kupchan S.M., Komoda Y., Branfman A.R., Sneden A.T., Court W.A., Thomas G.J., Hintz H.P., Smith R.M., Karim A., Howie G.A., Verma A.K., Nagao Y., Dailey R.G., Zimmerly V.A., Sumner Jr W.C. The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. J. Org. Chem. 1977, 42:2349-2357.
8. Mandelbaum-Shavit F., Wolpert-DeFilippes M.K., Johns D.G. Binding of maytansine to rat brain tubulin. Biochem. Biophys. Res. Commun. 1976, 72:47-54.
9. Bhattacharyya B., Wolff J. Maytansine binding to the vinblastine sites of tubulin. FEBS Lett. 1977, 75:159-162.
10. Blum R.H., Kahlert T. Maytansine: a phase I study of an ansa macrolide with antitumor activity. Cancer Treat. Rep. 1978, 62:435-438.
11. Issell B.F., Crooke S.T. Maytansine. Cancer Treat. Rev. 1978, 5:199-207.
12. Chabner B.A., Levine A.S., Johnson B.L., C Young R. Initial clinical trials of maytansine, an antitumor plant alkaloid. Cancer Treat. Rep. 1978, 62:429-433.
13. Eagan R.T., Creagan E.T., Ingle J.N., Frytak S., Rubin J. Phase II evaluation of maytansine in patients with metastatic lung cancer. Cancer Treat. Rep. 1978, 62:1577-1579.
14. Cabanillas F., Rodriguez V., Hall S.W., Burgess M.A., Bodey G.P., Freireich E.J. Phase I study of maytansine using a 3-day schedule. Cancer Treat. Rep. 1978, 62:425-428.
15. Cassady J.M., Chan K.K., Floss H.G., Leistner E. Recent developments in the maytansinoid antitumor agents. Chem. Pharm. Bull. (Tokyo) 2004, 52:1-26.
16. Borden E.C., Ash A., Enterline H.T., Rosenbaum C., Laucius J.F., Paul A.R., Falkson G., Lerner H. Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas. Am. J. Clin. Oncol. 1982, 5:417-420.
17. Ratanatharathorn V., Gad-el-Mawla N., Wilson H.E., Bonnet J.D., Rivkin S.E., Mass R. Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study. Cancer Treat. Rep. 1982, 66:1687-1688.
18. Thigpen J.T., Ehrlich C.E., Conroy J., Blessing J.A. Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix A. Gynecologic oncology group study. Am. J. Clin. Oncol. 1983, 6:427-430.
19. Chari R.V., Martell B.A., Gross J.L., Cook S.B., Shah S.A., Blättler W.A., McKenzie S.J., Goldmacher V.S. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 1992, 52:127-131.
20. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357:39-51.
21. Valabrega G., Capellero S., Cavalloni G., Zaccarello G., Petrelli A., Migliardi G., Milani A., Peraldo-Neia C., Gammaitoni L., Sapino A., Pecchioni C., Moggio A., Giordano S., Aglietta M., Montemurro F. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res. Treat. 2010, Available from: . 10.1007/s10549-010-1281-5.
22. Chari R.V. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 2008, 41:98-107.
23. Roguska M.A., Pedersen J.T., Keddy C.A., Henry A.H., Searle S.J., Lambert J.M., Goldmacher V.S., Blättler W.A., Rees A.R., Guild B.C. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. USA 1994, 91:969-973.
24. Pietersz G.A. The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of cancer. Bioconjug. Chem. 1990, 1:89-95.
25. Chari R.V. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv. Drug Deliv. Rev. 1998, 31:89-104.
26. Shen W.-C., Ryser H.J.-P. cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem. Biophys. Res. Commun. 1981, 102:1048-1054.
27. Widdison W.C., Wilhelm S.D., Cavanagh E.E., Whiteman K.R., Leece B.A., Kovtun Y., Goldmacher V.S., Xie H., Steeves R.M., Lutz R.J., Zhao R., Wang L., Blättler W.A., Chari R.V. Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 2006, 49:4392-4408.
28. Liu C., Tadayoni B.M., Bourret L.A., Mattocks K.M., Derr S.M., Widdison W.C., Kedersha N.L., Ariniello P.D., Goldmacher V.S., Lambert J.M., Blättler W.A., Chari R.V. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. USA 1996, 93:8618-8623.
29. Tolcher A.W., Ochoa L., Hammond L.A., Patnaik A., Edwards T., Takimoto C., Smith L., de Bono J., Schwartz G., Mays T., Jonak Z.L., Johnson R., DeWitte M., Martino H., Audette C., Maes K., Chari R.V., Lambert J.M., Rowinsky E.K. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. 2003, 21:211-222.
30. Polson A.G., Williams M., Gray A.M., Fuji R.N., Poon K.A., McBride J., Raab H., Januario T., Go M., Lau J., Yu S-F., Du C., Fuh F., Tan C., Wu Y., Liang W-C., Prabhu S., Stephan J-P., Hongo J-A., Dere R.C., Deng R., Cullen M., de Tute R., Bennett F., Rawstron A., Jack A., Ebens A. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 2010, 24:1566-1573.
31. F. Fossella, J. McCann, A. Tolcher, H. Xie, L. Hwang, C. Carr, K. Berg, R. Fram, Phase II Trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma, J. Clin. Oncology, ASCO Annual Meeting Proceedings. vol. 23, no. 16S, Part I of II (June 1 Supplement), 2005, p. 7159.
32. Galsky M.D., Eisenberger M., Moore-Cooper S., Kelly W.K., Slovin S.F., DeLaCruz A., Lee Y., Webb I.J., Scher H.I. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2008, 26:2147-2154.
33. Lutz R.J., Whiteman K.R. Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 2009, 1:548-551.
34. Goldenberg M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 1999, 21:309-318.
35. Isakoff S.J., Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-Positive breast cancer. J. Clin. Oncol. 2011, 29:351-354.
36. Thompson D., Patnaik A., Bendell J., Papadopoulos K., Infante J., Carrigan C., Vyas V., Mastico R.A., Johnson D., Qin A., O'Leary J., Tolcher A.W. A phase I dose-escalation study of IMGN388 in patients with solid tumors. J. Clin. Oncol. 2010, 28:15s. (suppl; abstr 3058).
37. Lambert J.M. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol. 2005, 5:543-549.
38. http://www.cancer.gov/drugdictionary/?CdrID=596550.
39. Lopus M., Oroudjev E., Wilson L., Wilhelm S., Widdison W., Chari R., Jordan M.A. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol. Cancer Ther. 2010, 9:2689-2699.
40. Yenjerla M., Lopus M., Wilson L. Analysis of dynamic instability of steady-state microtubules in vitro by video-enhanced differential interference contrast microscopy with an appendix by Emin Oroudjev. Methods Cell. Biol. 2010, 95:189-206.
41. Oroudjev E., Lopus M., Wilson L., Audette C., Provenzano C., Erickson H., Kovtun Y., Chari R., Jordan M.A. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol. Cancer Ther. 2010, 9:2700-2713.
42. Litvinov S.V., Velders M.P., Bakker H.A., Fleuren G.J., Warnaar S.O. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell. Biol. 1994, 125:437-446.
43. Kovtun Y.V., Audette C.A., Ye Y., Xie H., Ruberti M.F., Phinney S.J., Leece B.A., Chittenden T., Blättler W.A., Goldmacher V.S. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006, 66:3214-3221.
44. Kovtun Y.V., Audette C.A., Mayo M.F., Jones G.E., Doherty H., Maloney E.K., Erickson H.K., Sun X., Wilhelm S., Ab O., Lai K.C., Widdison W.C., Kellogg B., Johnson H., Pinkas J., Lutz R.J., Singh R., Goldmacher V.S., Chari R.V. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010, 70:2528-2537.
45. BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma (ID: NCT00346255). http://www.clinicaltrials.gov.
46. BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors (ID: NCT00346385). http://www.clinicaltrials.gov.
47. A Study of Trastuzumab-MCC-DM1 (T-DM1) in Combination With Docetaxel in Patients With Advanced Breast Cancer (ID: NCT00934856). http://www.clinicaltrials.gov.
48. A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE) (ID: NCT01120184). http://www.clinicaltrials.gov.
49. A Study of Trastuzumab-DM1 (T-DM1) Sequentially With Anthracycline-Based Chemotherapy, As Adjuvant or Neoadjuvant Therapy for Patients With Early Stage HER2-Positive Breast Cancer (ID: NCT01196052). http://www.clinicaltrials.gov.
50. A Study of Trastuzumab-MCC-DM1, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer (ID: NCT00951665). http://www.clinicaltrials.gov.